<div id="subtitle">Cancer drug developer soars on hopes for news</div><div><p>Shares of PharmaGap (TSX: V.GAP, Stock Forum) rallied 31% to 19 cents on Wednesday. </p><p>The company is a drug developer working on a cancer treatment. It has completed safety trials in some animal models. </p><p>The firm attended the BioPartnering conference in Vancouver this week, and posters to the company’s congenial Bullboard hoped for partnership announcement from the meetings. </p><p> “If the meetings went well then that might explain the action today,” wrote high_five. “ Peeps talk when there is something to talk about, like an undervalued biotech stock.” </p><p>KayDay forecasted a fresh announcement by mid February. </p><p>Others on the board discussed the appearance of the National Cancer Institute (NCI) of the U.S. on PharmaGap’s list of partners. </p><p>Trem_mar explained that the National Cancer Institute is not a partner, but rather it is: “testing toxicity on the drug, they should come out whit some result and data analyze in a short future. … there will be no partnership whit the NCI . the NCI won’t put any dollar in GAP … the only agreement they have whit GAP is to TEST more and give some DATA and analyze .. This worth GOLD when you present your drug to FDS or big pharma whit NCI full back up” </p><p>“I actually think this is a better agreement with the NCI as the politics aspect is now out. GAP has the free testing and non-cash backing, if there was a cash backing things could have been really tied up if GAP made any serious decisions in the future,” opined Alwyzl8t. </p><p></p><img src="http://admatch-syndication.mochila.com/images/ad.gif?aid=67935112&bid=informcom" /></div><div id="copyright"><div>

Copyright 2010  <a href="http://www.stockhouse.com">Stockhouse</a></div></div>